Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease DOI

Riccardo Righetti,

Felice Cinque,

Maria Teresa Volpe

et al.

Expert Review of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 18(7), P. 303 - 313

Published: July 2, 2024

The therapeutic landscape of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is rapidly evolving with the FDA approval resmetirom, first authorized molecule to treat metabolic dysfunction-associated steatohepatitis. Clinical trials are investigating other promising molecules. However, this focus on pharmacotherapy may overshadow lifestyle interventions, which remain cornerstone MASLD management. A significant percentage patients struggle an underlying eating disorder, often a precursor obesity. obesity pandemic, exacerbated by increasing prevalence binge eating, underscores need for psychological approach address their common roots.

Language: Английский

Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 DOI
Pojsakorn Danpanichkul,

Kanokphong Suparan,

Priyata Dutta

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 158, P. 155958 - 155958

Published: June 26, 2024

Language: Английский

Citations

29
Global Epidemiology of Alcohol-Related Liver Disease, Liver Cancer, and Alcohol Use Disorder, 2000–2021 DOI Creative Commons
Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan

et al.

Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 9, 2025

Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver (ALD). We aim to assess the global AUD, ALD, alcohol-attributable primary cancer between 2000-2021. registered regional trends using data from Global Burden Disease 2021 Study, largest most up-to-date epidemiology database. estimated annual percent change (APC) its 95% confidence interval (CI) changes in age-standardized rates over time. In 2021, there were 111.12 million cases 3.02 132,030 cancer. Between 2000 was 14.66% increase 38.68% 94.12% prevalence. While prevalence rate for increased (APC: 0.59%, [CI] 0.52 0.67%) these years, it decreased ALD -0.71%, CI -0.75 -0.67%) AUD -0.90%, -0.94 -0.86%). There significant variation by region, socioeconomic development level, sex. During last years (2019-2021), prevalence, incidence, death greater extent females. Given high cancer, urgent measures are needed prevent them at both national levels.

Language: Английский

Citations

5
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States DOI Open Access
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 5, 2025

ABSTRACT Objective Primary liver cancer (PLC) is projected to be the third leading cause of mortality in United States 2040. We examine burden PLC States, stratified by sex, state and aetiological risk factors. Methods Data on prevalence, incidence, death disability–adjusted life years (DALYs) were extracted from Global Burden Disease Study 2021. Changes these parameters calculated using Joinpoint regression model. Results There 47,970 cases, 31,450 incident 24,770 deaths 576,920 DALYs States. The highest prevalence (16,980), incidence (12,040), (9840) (213,410) due chronic hepatitis C virus infection. From 2000 2021, incidences increased 141%, 136%. Age–standardised rates (ASIRs) (ASDRs) per 100,000 population for increased, primarily driven alcohol–related disease (ALD) (ASIR: annual percent change [APC]: +2.40%; ASDR: APC: +2.22%) metabolic dysfunction–associated steatotic (MASLD) +2.32%; +2.04%). Conclusion has risen past two decades, mainly ALD followed MASLD. These findings offer policymakers an accurate assessment emphasise need targeted factor mitigation, especially regarding alcohol related policy.

Language: Английский

Citations

4
Mortality of gastrointestinal cancers attributable to smoking, alcohol, and metabolic risk factors, and its association with socioeconomic development status 2000–2021 DOI
Pojsakorn Danpanichkul, Kanokphong Suparan,

Yanfang Pang

et al.

The American Journal of Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Increased MASH-associated liver cancer in younger demographics DOI Creative Commons
Pojsakorn Danpanichkul,

Yanfang Pang,

Kanokphong Suparan

et al.

Hepatology Communications, Journal Year: 2025, Volume and Issue: 9(1)

Published: Jan. 1, 2025

Background: The incidence of cancer and the prevalence metabolic disease dysfunction–associated steatotic liver is increasing in young adults. However, updated global data on steatohepatitis (MASH)-associated primary (PLC) adults remains scarce. Methods: This study analyzed from Global Burden Disease between 2000 2021 to assess age-standardized incidence, mortality, disability-adjusted life years rates MASH-associated PLC (15–49 y). Results: In 2021, there were 4300 cases, 3550 deaths, 179,340 Among various etiologies adults, only had increased (annual percent change: +0.26, 95% CI: 0.16%–0.35%), with Eastern Mediterranean region having largest observed increase 1.46%, 1.40%–1.51%). made up 6% (+1% 2000) incident (+2% all this age group. Over half countries exhibited an rate 2021. Conclusions: significantly increasing, signaling likely future increases among older as cohort ages. trend necessitates urgent strategies worldwide mitigate epidemics

Language: Английский

Citations

1
Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder DOI Open Access

Chia‐Chih Kuo,

Chun‐Hsien Li, Min‐Hsiang Chuang

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in reducing alcohol consumption, but their impact on clinical outcomes patients with use disorder (AUD) remains unclear. We investigated the association between GLP-1RAs and development progression of alcohol-related liver disease (ArLD) AUD. Using TriNetX Research Network, we conducted two retrospective cohort studies comparing versus dipeptidyl peptidase-4 inhibitors (DPP-4is) type 2 diabetes. The first included AUD without ArLD (n = 7132 after propensity score matching), while second comprised established 1896 matching). Primary were incident hepatic decompensation cohort. In (median follow-up: 63.2 months), GLP-1RA users showed significantly lower risks developing compared to DPP-4i (incidence rate: 6.0 vs. 8.7 per 1000 person-years; HR: 0.62, 95% CI: 0.44-0.87, p 0.006). also associated reduced all-cause mortality (HR: 0.53, < 0.001). 28.2 demonstrated 39.5 51.4 0.66, 0.51-0.85, 0.001) users. progressing AUD, suggesting potential therapeutic benefits this population.

Language: Английский

Citations

1
Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake DOI
Majd B. Aboona, Pojsakorn Danpanichkul, Vincent Chen

et al.

Journal of Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 39(11), P. 2456 - 2463

Published: Aug. 22, 2024

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has become a leading cause of chronic worldwide. A new entity termed MetALD also been described is defined as individuals with MASLD increased alcohol intake. However, the natural history compared unknown. We aimed to compare longitudinal outcomes in patients versus MetALD. Methods This study was performed using data from National Health Nutrition Examination Survey 2011 2018. (defined by United States Fatty Liver Index > 30) who met cardiometabolic criteria including body mass index (BMI) 25 (BMI 23 Asians), hypertension, diabetes mellitus, dyslipidemia, hypertriglyceridemia were included. intake (3–6 standard drinks per day males; 2–5 females). comparison overall, cardiovascular, cancer‐related, other causes mortality performed. Results total 2838 2557 included median follow‐up time 56 months. at risk cancer‐related (hazard ratio 1.32; 95% confidence interval 1.14–1.53; P < 0.01). there no significant difference mortality. Conclusions Patients higher for than MASLD. Close attention regular cancer surveillance accurate classification consumption diagnosed warranted help improve patient care outcome.

Language: Английский

Citations

8
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment DOI Creative Commons
Soo Young Hwang, Pojsakorn Danpanichkul, Vatche G. Agopian

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 26, 2024

Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.HCC due to chronic hepatitis B virus (HBV) or C (HCV) infection has decreased universal vaccination for HBV and effective antiviral therapy both HCV, but HCC related metabolic dysfunction associated steatotic liver disease (MASLD) alcohol-associated (ALD) increasing.Biannual ultrasonography serum α-fetoprotein are primary surveillance tools early detection among high-risk patients (e.g., cirrhosis, HBV).Alternative such blood-based biomarker panels abbreviated MRIs being investigated.Multiphasic CT MRI standard diagnosis, histological confirmation should be considered, especially when inconclusive findings seen on cross-sectional imaging.Staging treatment decisions complex made in multidisciplinary settings, incorporating multiple factors including tumor degree dysfunction, patient performance status, available expertise, preferences.Early-stage best treated with curative options resection, ablation, transplantation.For intermediatestage disease, locoregional therapies primarily recommended although systemic may preferred large intrahepatic burden.In advanced-stage immune checkpoint inhibitor (ICI)-based regimen.In this review article, we discuss recent epidemiology, risk factors, care continuum encompassing surveillance, staging, treatments.

Language: Английский

Citations

7
Global burden and cross-country health inequalities of early-onset colorectal cancer and its risk factors from 1990 to 2021 and its projection until 2036 DOI Creative Commons
Jinhai Zhang, Dehua Ou,

Aosi Xie

et al.

BMC Public Health, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 12, 2024

To explore the worldwide, regional, and country-specific burden of early-onset colorectal cancer (EO-CRC) identify its associated risk factors between 1990 2021, to project incidence mortality rates for 2036. We acquired data on EO-CRC categorized by gender, socio-demographic index (SDI), based Global Burden Disease (GBD) Study 2021. Joinpoint regression analysis was utilized variation in disease burden. The autoregressive integrated moving average (ARIMA) model performed forecast up Globally, rate, prevalence disability-adjusted life years (DALYs) rate were estimated at 5.37 (95%UI: 4.91 5.86)/100,000, 34 30.96 37.35)/100,000, 2.01 1.84 2.19)/100,000, 101.37 (95%: 92.85 110.18)/100,000 showed an ascending trajectory, whilst DALYs demonstrated a downward trajectory high-middle SDI regions East Asia exhibited highest among five 21 GBD respectively. A low-whole-grains diet chief factor contributing EO-CRC. It predicted that age-standardized (ASR) would increase 5.56%, while ASR decrease 13.9% globally until current future global is heavy varies significantly across different countries.

Language: Английский

Citations

6
Global, regional and country burden of high BMI-related liver cancer among individuals aged above 70: trends from 1990 to 2021 and projections to 2044 DOI Creative Commons
Ke‐Jie He,

Wensheng Shu,

Yanggang Hong

et al.

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 13

Published: March 20, 2025

Background Liver cancer (LC) is a major global health concern, being the fourth leading cause of cancer-related mortality. Older adults are more susceptible, though mortality rates for those over 70 declining. However, disability from non-communicable diseases remains high. High body mass index (BMI) notable risk factor LC, with high BMI-related liver (HB-LC) concern. Methods This study utilized Global Burden Disease (GBD) 2021 dataset to assess impact HB-LC on individuals aged and older 1990 2021, forecasts extending 2044. burden across socio-demographic (SDI) regions was evaluated using age-standardized disability-adjusted life years (DALYs). Joinpoint regression age-period-cohort models were used analyze DALY trends demographic influences, decomposition analysis assessed effects population aging, growth, epidemiological shifts. Results Our findings revealed significant geographical disparities in mortality, East Asia, Southeast parts West Africa showing highest rates. DALYs increased by 2.49% annually, low SDI experiencing recent acceleration. Gender disparity persisted, males facing steeper rise burden. Age-related peaked 80–89 age groups, complex patterns regions. Epidemiological changes primarily drove regions, while growth Conclusion data underscores necessity region-specific public strategies demographic-focused interventions, enhancing surveillance targeting efforts mitigate increasing among adults.

Language: Английский

Citations

0